Tumor Abnormality-Oriented Nanomedicine Design,Chemical Reviews

当前位置： X-MOL 学术 › Chem. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Tumor Abnormality-Oriented Nanomedicine Design
Chemical Reviews ( IF 51.4 ) Pub Date : 2023-09-15 , DOI: 10.1021/acs.chemrev.3c00062
Quan Zhou _{1,

2,

3} , Jiajia Xiang _{1,

2,

3} , Nasha Qiu _{1,

2} , Yechun Wang ₃ , Ying Piao _{1,

2} , Shiqun Shao _{1,

2} , Jianbin Tang _{1,

2} , Zhuxian Zhou _{1,

2} , Youqing Shen _{1,

2,

4}

Affiliation

Anticancer nanomedicines have been proven effective in mitigating the side effects of chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic efficacy. Nanomedicines responsive to the pathological abnormalities in the tumor microenvironment (TME) are expected to overcome the biological limitations of conventional nanomedicines, enhance the therapeutic efficacies, and further reduce the side effects. This Review aims to quantitate the various pathological abnormalities in the TME, which may serve as unique endogenous stimuli for the design of stimuli-responsive nanomedicines, and to provide a broad and objective perspective on the current understanding of stimuli-responsive nanomedicines for cancer treatment. We dissect the typical transport process and barriers of cancer drug delivery, highlight the key design principles of stimuli-responsive nanomedicines designed to tackle the series of barriers in the typical drug delivery process, and discuss the “all-into-one” and “one-for-all” strategies for integrating the needed properties for nanomedicines. Ultimately, we provide insight into the challenges and future perspectives toward the clinical translation of stimuli-responsive nanomedicines.

中文翻译：

面向肿瘤异常的纳米药物设计

抗癌纳米药物已被证明可以有效减轻化疗药物的副作用。然而，在增强其治疗功效方面仍然存在挑战。响应肿瘤微环境（TME）病理异常的纳米药物有望克服传统纳米药物的生物学局限性，提高治疗效果，并进一步减少副作用。本综述旨在量化 TME 中的各种病理异常，这些异常可能作为刺激响应性纳米药物设计的独特内源性刺激，并为当前对用于癌症治疗的刺激响应性纳米药物的理解提供广泛而客观的视角。我们剖析了癌症药物递送的典型运输过程和障碍，重点介绍了旨在解决典型药物递送过程中一系列障碍的刺激响应性纳米药物的关键设计原则，并讨论了“全合一”和“一体”整合纳米药物所需特性的“全民”策略。最终，我们深入了解刺激响应纳米药物临床转化的挑战和未来前景。

更新日期：2023-09-15

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南